Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

How effective is fluoxetine for the treatment of pain and constipation-predominant irritable bowel syndrome?

Nature Clinical Practice Gastroenterology & Hepatology volume 3, pages 196–197 (2006)Cite this article

boxed-textVahedi H et al. (2005) The effect of fluoxetine in patients with pain and constipationpredominant irritable bowel syndrome: a double-blind study. Aliment Pharmacol Ther 22: 381–385

Clinicians might consider using a selective serotonin reuptake inhibitor in standard doses for patients with refractory, constipation-predominant irritable bowel syndrome, but a benefit is not yet established

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Gorard DA et al. (1994) Influence of antidepressants on whole gut orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther 8: 159–166

    Article  CAS  Google Scholar 

  2. Chial HJ et al. (2003) Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans. Clin Gastroenterol Hepatol 1: 211–218

    Article  CAS  Google Scholar 

  3. Coates MD et al. (2004) Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 126: 1657–1664

    Article  CAS  Google Scholar 

  4. Creed F et al. (2003) The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 124: 303–317

    Article  Google Scholar 

  5. Kuiken SD et al. (2003) The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastoenterol Hepatol 1: 219–228

    Article  CAS  Google Scholar 

  6. Weinrieb RM et al. (2005) Selective serotonin re-uptake inhibitors and the risk of bleeding. Expert Opin Drug Saf 4: 337–344

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Rachel Jones, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professor of Medicine and the Director of the Motility Interest Group in the Division of Gastroenterology and Hepatology at the Mayo Clinic in Rochester, MN, USA

    Nicholas J Talley

Authors
  1. Nicholas J Talley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicholas J Talley.

Ethics declarations

Competing interests

Nicholas J Talley is a consultant for AstraZeneca, Axcan, EBMed, Giaconda, Medscape, Solvay, Theravance, Yamanouchi, Boehringer-Ingelheim, and Chugai. He receives research support from Merck, Novartis, and Tap Pharmaceuticals.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Talley, N. How effective is fluoxetine for the treatment of pain and constipation-predominant irritable bowel syndrome?. Nat Rev Gastroenterol Hepatol 3, 196–197 (2006). https://doi.org/10.1038/ncpgasthep0444

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep0444

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing